Skip to main content
Journal cover image

Melatonin and risk of mortality in subjects with aneurysmal subarachnoid hemorrhage.

Publication ,  Journal Article
Lin, SH; Galet, C; Zanaty, M; Bayman, E; Rogers, WK; Hasan, D; Allan, LD
Published in: Clin Neurol Neurosurg
November 2021

BACKGROUND: Delayed cerebral ischemia (DCI) is a cause of morbidity associated with aneurysmal subarachnoid hemorrhage (aSAH). Neuroinflammation contributes to the development of DCI. Melatonin is a sleep-promoting hormone known to have cerebral anti-inflammatory properties. We hypothesized that synthetic melatonin (or the selective melatonin receptor agonist ramelteon) incidentally prescribed to improve sleep may lower the incidence of DCI among hospitalized aSAH patients. METHODS: Subjects with a Hunt and Hess Grade I-III were identified from a data registry involving all aSAH patients admitted to our hospital between January 2015 and September 1, 2018. A cohort of patients who received either melatonin or ramelteon during their hospitalization was compared to a matched cohort that did not receive these drugs. The primary endpoint was incidence of DCI. Secondary outcomes included modified Rankin score (mRS) at discharge, discharge destination, and mortality at 6 weeks from discharge. The two groups were compared using univariate analysis. P < 0.05 was considered significant. RESULTS: There was no significant difference in the incidence of DCI (15.8% vs. 16.9%, p = 1), discharge mRS (mRS 0-3: 51.3% vs. 45.1%, p = 0.59), discharge disposition (Home: 43.6% vs. 44.4, p = 0.47), or mortality (0% vs. 9.2%; p = 0.074) between the melatonin/ramelteon and non-melatonin groups. CONCLUSION: The use melatonin had no effect on DCI but may improve mortality in aSAH subjects. Prospective studies using a larger cohort are warranted to validate these findings.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Neurol Neurosurg

DOI

EISSN

1872-6968

Publication Date

November 2021

Volume

210

Start / End Page

106990

Location

Netherlands

Related Subject Headings

  • Subarachnoid Hemorrhage
  • Risk Factors
  • Retrospective Studies
  • Registries
  • Neurology & Neurosurgery
  • Mortality
  • Middle Aged
  • Melatonin
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lin, S. H., Galet, C., Zanaty, M., Bayman, E., Rogers, W. K., Hasan, D., & Allan, L. D. (2021). Melatonin and risk of mortality in subjects with aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg, 210, 106990. https://doi.org/10.1016/j.clineuro.2021.106990
Lin, Suzy H., Colette Galet, Mario Zanaty, Emine Bayman, William K. Rogers, David Hasan, and Lauren D. Allan. “Melatonin and risk of mortality in subjects with aneurysmal subarachnoid hemorrhage.Clin Neurol Neurosurg 210 (November 2021): 106990. https://doi.org/10.1016/j.clineuro.2021.106990.
Lin SH, Galet C, Zanaty M, Bayman E, Rogers WK, Hasan D, et al. Melatonin and risk of mortality in subjects with aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 2021 Nov;210:106990.
Lin, Suzy H., et al. “Melatonin and risk of mortality in subjects with aneurysmal subarachnoid hemorrhage.Clin Neurol Neurosurg, vol. 210, Nov. 2021, p. 106990. Pubmed, doi:10.1016/j.clineuro.2021.106990.
Lin SH, Galet C, Zanaty M, Bayman E, Rogers WK, Hasan D, Allan LD. Melatonin and risk of mortality in subjects with aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 2021 Nov;210:106990.
Journal cover image

Published In

Clin Neurol Neurosurg

DOI

EISSN

1872-6968

Publication Date

November 2021

Volume

210

Start / End Page

106990

Location

Netherlands

Related Subject Headings

  • Subarachnoid Hemorrhage
  • Risk Factors
  • Retrospective Studies
  • Registries
  • Neurology & Neurosurgery
  • Mortality
  • Middle Aged
  • Melatonin
  • Male
  • Humans